Cargando…
Personalizing immunotherapy: Balancing predictability and precision
Despite great expectations and research efforts, anticancer immunotherapy has not yet become a definitive cure. Perhaps, this is because past reductionist approaches were too simplistic for the patient-specific complex system of co-evolving tumor cells and host immunity. Recent efforts based on a sy...
Autores principales: | Agur, Zvia, Vuk-Pavlović, Stanimir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494634/ https://www.ncbi.nlm.nih.gov/pubmed/23170268 http://dx.doi.org/10.4161/onci.20955 |
Ejemplares similares
-
Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models
por: Kronik, Natalie, et al.
Publicado: (2010) -
RIPK3—a predictive marker for personalized immunotherapy?
por: Smola, Sigrun
Publicado: (2015) -
Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy
por: Wimmers, Florian, et al.
Publicado: (2014) -
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015) -
Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)